

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7332104

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PAUL H. SONG	05/12/2022
GANG QIN	05/11/2022
CHONG LIU	05/11/2022
RECEIVING PARTY DATA	
Name:	GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
Street Address:	RUOSHUI RD. 398, 5TH FLOOR
Internal Address:	BUILDING D
City:	SUZHOU INDUSTRIAL PARK
State/Country:	CHINA
Postal Code:	215213
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17689198
CORRESPONDENCE DATA	
Fax Number:	(973)912-5236
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9739125232
Email:	file@hoxpat.com
Correspondent Name:	HOXIE & ASSOCIATES
Address Line 1:	75 MAIN STREET
Address Line 2:	SUITE 203
Address Line 4:	MILLBURN, NEW JERSEY 07041
ATTORNEY DOCKET NUMBER:	GQH-09-US
NAME OF SUBMITTER:	SANGIL LEE
SIGNATURE:	/Sangil Lee/
DATE SIGNED:	05/16/2022
Total Attachments: 6	
source=GQH-09-US_Executed_Assignment#page1.tif	
source=GQH-09-US_Executed_Assignment#page2.tif	

source=GQH-09-US_Executed_Assignment#page3.tif

source=GQH-09-US_Executed_Assignment#page4.tif

source=GQH-09-US_Executed_Assignment#page5.tif

source=GQH-09-US_Executed_Assignment#page6.tif

ASSIGNMENT

WHEREAS I/We, the below named inventor(s) (hereinafter referred to as ASSIGNOR(S)) have made an invention entitled:

ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF

for which I/We filed a patent application on March 8, 2022, as U.S. Patent Application No. 17/689,198, which claims priority to and the benefit of International Application No. PCT/CN2021/079609, filed March 8, 2021; and

WHEREAS, GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD., a corporation of China whose post office address is Ruoshui Rd. 398, 5th floor, Building D, Suzhou Industrial Park, China, 215123 (hereinafter referred to as ASSIGNEE), is desirous of securing the entire right, title, and interest in and to the aforesaid invention and/or any improvements thereon in all countries throughout the world, and in and to the application(s) for Letters Patent on the aforesaid invention and/or any improvements thereon and the Letters Patent to be issued upon the aforesaid U.S. and/or International application(s);

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR(S), by these presents do sell, assign and transfer to ASSIGNEE, the full and exclusive right, title and interest in and to the aforesaid invention and any improvements thereon, the aforesaid application(s) and all corresponding and/or counterpart foreign patent applications, all divisional, continuation, continuation-in-part, reissue, reexamination, extension, substitution, registration, renewal, extension, Supplementary Protection Certificates or the like, and any additional patent applications which claim priority to the aforesaid application(s), and all Letters Patent or comparable rights issuing thereon in the United States and in all foreign countries, and all applications for Letters Patent which may hereafter be filed for the aforesaid invention and/or any improvements thereon in the United States and/or in any foreign country and all Letters Patent which may be granted on the aforesaid invention and/or any improvements thereon in the United States and/or in any foreign country, together with the right(s) to claim priority to the aforesaid patent application(s) and/or any improvements thereon, and the ASSIGNOR(S) hereby authorize and request the United States Commissioner of Patents and Trademarks and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent or comparable rights issuing on any application as aforesaid to ASSIGNEE, or to its successors, assigns or legal representatives;

ASSIGNOR(S) hereby covenant that ASSIGNOR(S) have full right to convey the entire interest herein assigned, and that ASSIGNOR(S) have not executed, and will not execute, any agreement in conflict herewith;

ASSIGNOR(S) agree to communicate to ASSIGNEE or to its successors, assigns or legal representatives any and all facts known to them or any of them respecting said invention, and without further remuneration to testify in any legal proceeding, sign all lawful papers, execute all divisional, continuation, continuation-in-part, reissue and reexamination applications, make all rightful oaths and generally do all lawful acts to aid ASSIGNEE or its successors, assigns or legal representatives to obtain and enforce proper patent protection for said invention in all

countries and to enhance or perfect ASSIGNEE's title in and to the invention and patent rights therein.

ASSIGNOR(S) hereby authorize attorneys for ASSIGNEE to enter on this document any applicable serial numbers and filing dates after ASSIGNOR(S)' execution of this document.

ASSIGNOR(S) hereby acknowledge an obligation to assign and do hereby assign all right, title and interest in and to the aforesaid invention and any improvements thereon to ASSIGNEE at the time the invention was made.

This Assignment may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN TESTIMONY WHEREOF, I hereunto set my hand and seal on _____ 2022.

Name: **Paul H. SONG**

IN TESTIMONY WHEREOF, I hereunto set my hand and seal on 11th May 2022.

Name: **Gang QIN**

IN TESTIMONY WHEREOF, I hereunto set my hand and seal on _____ 2022.

Name: **Chong LIU**

Countersign by an authorized party on behalf of the ASSIGNEE:

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 11th day of May _____ 2022.

Name:

Title:

Genequantum Healthcare (Suzhou) Co., Ltd.

Authorized Representative of Assignee

ASSIGNMENT

WHEREAS I/We, the below named inventor(s) (hereinafter referred to as ASSIGNOR(S)) have made an invention entitled:

ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF

for which I/We filed a patent application on March 8, 2022, as U.S. Patent Application No. 17/689,198, which claims priority to and the benefit of International Application No. PCT/CN2021/079609, filed March 8, 2021; and

WHEREAS, GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD., a corporation of China whose post office address is Ruoshui Rd. 398, 5th floor, Building D, Suzhou Industrial Park, China, 215123 (hereinafter referred to as ASSIGNEE), is desirous of securing the entire right, title, and interest in and to the aforesaid invention and/or any improvements thereon in all countries throughout the world, and in and to the application(s) for Letters Patent on the aforesaid invention and/or any improvements thereon and the Letters Patent to be issued upon the aforesaid U.S. and/or International application(s);

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR(S), by these presents do sell, assign and transfer to ASSIGNEE, the full and exclusive right, title and interest in and to the aforesaid invention and any improvements thereon, the aforesaid application(s) and all corresponding and/or counterpart foreign patent applications, all divisional, continuation, continuation-in-part, reissue, reexamination, extension, substitution, registration, renewal, extension, Supplementary Protection Certificates or the like, and any additional patent applications which claim priority to the aforesaid application(s), and all Letters Patent or comparable rights issuing thereon in the United States and in all foreign countries, and all applications for Letters Patent which may hereafter be filed for the aforesaid invention and/or any improvements thereon in the United States and/or in any foreign country and all Letters Patent which may be granted on the aforesaid invention and/or any improvements thereon in the United States and/or in any foreign country, together with the right(s) to claim priority to the aforesaid patent application(s) and/or any improvements thereon, and the ASSIGNOR(S) hereby authorize and request the United States Commissioner of Patents and Trademarks and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent or comparable rights issuing on any application as aforesaid to ASSIGNEE, or to its successors, assigns or legal representatives;

ASSIGNOR(S) hereby covenant that ASSIGNOR(S) have full right to convey the entire interest herein assigned, and that ASSIGNOR(S) have not executed, and will not execute, any agreement in conflict herewith;


ASSIGNOR(S) agree to communicate to ASSIGNEE or to its successors, assigns or legal representatives any and all facts known to them or any of them respecting said invention, and without further remuneration to testify in any legal proceeding, sign all lawful papers, execute all divisional, continuation, continuation-in-part, reissue and reexamination applications, make all rightful oaths and generally do all lawful acts to aid ASSIGNEE or its successors, assigns or legal representatives to obtain and enforce proper patent protection for said invention in all

countries and to enhance or perfect ASSIGNEE's title in and to the invention and patent rights therein.

ASSIGNOR(S) hereby authorize attorneys for ASSIGNEE to enter on this document any applicable serial numbers and filing dates after ASSIGNOR(S)' execution of this document.

ASSIGNOR(S) hereby acknowledge an obligation to assign and do hereby assign all right, title and interest in and to the aforesaid invention and any improvements thereon to ASSIGNEE at the time the invention was made.

This Assignment may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN TESTIMONY WHEREOF, I hereunto set my hand and seal on 12th May 2022.

Name: **Paul H. SONG**

IN TESTIMONY WHEREOF, I hereunto set my hand and seal on _____ 2022.
Name: **Gang QIN**

IN TESTIMONY WHEREOF, I hereunto set my hand and seal on _____ 2022.
Name: **Chong LIU**

Countersign by an authorized party on behalf of the ASSIGNEE:

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this _____ day of _____ 2022.

Name:
Title:
Genequantum Healthcare (Suzhou) Co.,
Ltd.
Authorized Representative of Assignee

ASSIGNMENT

WHEREAS I/We, the below named inventor(s) (hereinafter referred to as ASSIGNOR(S)) have made an invention entitled:

ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF

for which I/We filed a patent application on March 8, 2022, as U.S. Patent Application No. 17/689,198, which claims priority to and the benefit of International Application No. PCT/CN2021/079609, filed March 8, 2021; and

WHEREAS, GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD., a corporation of China whose post office address is Ruoshui Rd. 398, 5th floor, Building D, Suzhou Industrial Park, China, 215123 (hereinafter referred to as ASSIGNEE), is desirous of securing the entire right, title, and interest in and to the aforesaid invention and/or any improvements thereon in all countries throughout the world, and in and to the application(s) for Letters Patent on the aforesaid invention and/or any improvements thereon and the Letters Patent to be issued upon the aforesaid U.S. and/or International application(s);

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR(S), by these presents do sell, assign and transfer to ASSIGNEE, the full and exclusive right, title and interest in and to the aforesaid invention and any improvements thereon, the aforesaid application(s) and all corresponding and/or counterpart foreign patent applications, all divisional, continuation, continuation-in-part, reissue, reexamination, extension, substitution, registration, renewal, extension, Supplementary Protection Certificates or the like, and any additional patent applications which claim priority to the aforesaid application(s), and all Letters Patent or comparable rights issuing thereon in the United States and in all foreign countries, and all applications for Letters Patent which may hereafter be filed for the aforesaid invention and/or any improvements thereon in the United States and/or in any foreign country and all Letters Patent which may be granted on the aforesaid invention and/or any improvements thereon in the United States and/or in any foreign country, together with the right(s) to claim priority to the aforesaid patent application(s) and/or any improvements thereon, and the ASSIGNOR(S) hereby authorize and request the United States Commissioner of Patents and Trademarks and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent or comparable rights issuing on any application as aforesaid to ASSIGNEE, or to its successors, assigns or legal representatives;

ASSIGNOR(S) hereby covenant that ASSIGNOR(S) have full right to convey the entire interest herein assigned, and that ASSIGNOR(S) have not executed, and will not execute, any agreement in conflict herewith;

ASSIGNOR(S) agree to communicate to ASSIGNEE or to its successors, assigns or legal representatives any and all facts known to them or any of them respecting said invention, and without further remuneration to testify in any legal proceeding, sign all lawful papers, execute all divisional, continuation, continuation-in-part, reissue and reexamination applications, make all rightful oaths and generally do all lawful acts to aid ASSIGNEE or its successors, assigns or legal representatives to obtain and enforce proper patent protection for said invention in all

(Sheet 1 of 2)

countries and to enhance or perfect ASSIGNEE's title in and to the invention and patent rights therein.

ASSIGNOR(S) hereby authorize attorneys for ASSIGNEE to enter on this document any applicable serial numbers and filing dates after ASSIGNOR(S)' execution of this document.

ASSIGNOR(S) hereby acknowledge an obligation to assign and do hereby assign all right, title and interest in and to the aforesaid invention and any improvements thereon to ASSIGNEE at the time the invention was made.

This Assignment may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN TESTIMONY WHEREOF, I hereunto set my hand and seal on _____ 2022.

Name: **Paul H. SONG**

IN TESTIMONY WHEREOF, I hereunto set my hand and seal on _____ 2022.

Name: **Gang QIN**

IN TESTIMONY WHEREOF, I hereunto set my hand and seal on 11th May 2022.

Name: **Chong LIU**

Countersign by an authorized party on behalf of the ASSIGNEE:

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this _____ day of _____
_____ 2022.

Name:

Title:

Genequantum Healthcare (Suzhou) Co.,
Ltd.

Authorized Representative of Assignee